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Background: In March, 2007, a black box warning was issued by the Food and Drug Administration (FDA) to use
the lowest possible erythropoiesis-stimulating agents (ESA) doses for treatment of anemia associated with renal
disease. The goal is to determine if a change in ESA use was observed following the warning among US dialysis
patients.
Methods: ESA therapy was examined from September 2004 through August 2009 (thirty months before and after
the FDA black box warning) among adult Medicare hemodialysis patients. An interrupted time series model
assessed the impact of the warnings.
Results: The FDA black box warning did not appear to influence ESA prescribing among the overall dialysis
population. However, significant declines in ESA therapy after the FDA warnings were observed for selected
populations. Patients with a hematocrit ≥36% had a declining month-to-month trend before (−164 units/week,
p = <0.0001) and after the warnings (−80 units/week, p = .001), and a large drop in ESA level immediately after the
black box (−4,744 units/week, p = <.0001). Not-for-profit facilities had a declining month-to-month trend before the
warnings (−90 units/week, p = .009) and a large drop in ESA dose immediately afterwards (−2,487 units/week,
p = 0.015). In contrast, for-profit facilities did not have a significant change in ESA prescribing.
Conclusions: ESA therapy had been both profitable for providers and controversial regarding benefits for nearly
two decades. The extent to which a FDA black box warning highlighting important safety concerns influenced use
of ESA therapy among nephrologists and dialysis providers was unknown. Our study found no evidence of changes
in ESA prescribing for the overall dialysis population resulting from a FDA black box warning.
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Anemia affects nearly all end-stage renal disease (ESRD)
patients and is associated with reduced quality of life
and decreased survival rates [1-3]. In 1987, investigators
reported successful use of erythropoietin stimulating
agents (ESA also known as rHuEPO, epoetin or EPO, trade
name EPOGEN®) in treating the anemia by elevating
the hematocrit level of ESRD patients and reducing
transfusions. Between 1991 and 2005, the mean ESA
dose increased about four-fold in dialysis patients [4]. In* Correspondence: dcott@mtppi.org
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reproduction in any medium, provided the or2007, Medicare expenditures for ESAs for ESRD patients
were ~ $1.65 billion [5]. Randomized trials found an
increase in vascular access thrombosis and a trend
towards death and heart attacks among dialysis patients [6],
and an increased risk of a composite endpoint including
death and cardiovascular events among predialysis patients
targeted to higher hematocrit levels [7]. A third study found
no difference in harm or benefit in the study arms [8]. As
a result, on March 9, 2007, FDA issued a black box public
health warning to physicians to adjust the ESA dose to
maintain the lowest hemoglobin level needed to avoid
the need for blood transfusions. According to the FDA,
“physicians and patients should carefully weigh the risks
of ESAs against transfusion risks.” The goal of this studyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of patients receiving ESA therapy













18–44 13.5 13.6 13.4
45–64 37.9 37.1 38.6
≥65 48.6 49.3 48.0
Race 0.329
White 54.6 54.6 54.6
Non-white 45.4 45.4 45.4
Gender <.0001
Male 53.7 53.4 53.9
Female 46.3 46.6 46.1
Duration of dialysis <.0001
<12 months 20.3 21.2 19.5
12– < 36 months 29.5 29.9 29.2
≥36 months 50.1 48.9 51.3
Diabetes co-morbidity <.0001
Diabetic 44.3 44.0 44.6
Non-diabetic 55.7 56.0 55.4
Facility profit status <.0001
For-profit 81.2 80.5 82.0
Non-profit 18.8 19.5 18.0
Facility chain status <.0001
Chain 1 (FP) 27.0 26.9 27.0
Chain 2 (FP) 30.4 26.8 33.9
Chain 3 (NP) 4.0 4.1 3.9
Medium chain 10.8 13.0 8.8
Small/non chains 17.8 18.7 16.9
Hospital-based (NP) 10.0 10.6 9.5
Hematocrit value# <.0001
<30% 8.4 7.4 9.4
30– < 36% 45.7 41.6 49.8
≥36% 45.9 51.0 40.8
Notes: FP For-profit, NP Nonprofit.
Base period from September 2004 to February 2007. Followup MArch 2007 to
August 2009.
FDA black box warning was issuedin March 2007.
#Patients months with missing hematocrit values are not included (when dose
is withheld).
*P-value for Pearson’s chi-square test based on the difference between pre
and post FDA warning period.
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ESA therapy as a result of the FDA warnings.
Methods
Data sources and study design
We used data from the United States Renal Data System
(USRDS) Standard Analytic Files (SAFs) to conduct this
study [9]. USRDS data system is a national resource that
includes demographic and clinical data on ~97% of all
US ESRD patients and their institutional providers of
dialysis treatment. (The USRDS website, http://www.
usrds.org, “Researcher’s Guide to the USRDS Database”
describes the variables, data source, collection methods,
and validation studies.) The hematocrit reading taken
prior to the first administration of ESA therapy during
the billing period (usually the beginning of the month)
was submitted for payment with the total dose of ESA
administered over the exposure period.
Specifically, September 2004 to February 2007 was
chosen as the 30-month base period (prior to the FDA
black box warning) and March 2007 to August 2009 was
chosen as the 30-month follow-up period. ESA therapy
is usually administered during outpatient dialysis via
intravenous administration three times a week. In an effort
to stabilize a large increase in hematocrit, physicians will
periodically prescribe a zero ESA dose for a particular
month. We also include these so-called zero dose months
in our analysis. To ensure the availability of claims, the
study population was restricted to adult ESRD hemodialysis
patients with Medicare as a primary payor indicated by a
variable in the USRDS Payor History File. We excluded
those patients with MSP because they have incomplete
ESA data since their primary (usually private) payor is likely
to get billed for ESA therapy. Our study period included
only one form of ESA (alfa epoetin) for treatment of
anemia associated with renal failure.
Covariates used for subanalyses are listed in Tables 1 & 2.
Age was categorized as follows: 18 – 44, 45 – 64,
and ≥ 65 years. Race was categorized as White or non-
white. Duration of dialysis was determined as: <12,
12 - <36, and ≥ 36 months. Diabetes was determined if it
was reported to be the primary cause of renal failure and/
or diabetes was listed as a co-morbid condition when a
patient enrolls in the Medicare ESRD program. Dialysis
organizational status was defined by: 1) chain membership
(based on size and affiliation); and 2) profit status.
Interrupted time series analysis
Trends in anemia treatment before and after the FDA
Public Health Advisory were statistically analyzed by
categorical methods and interrupted time series models
[10,11]. To determine if there was a differential impact
resulting from the FDA black box warning, we stratified our
analyses by demographic, clinical, and facility characteristics.Trends in ESA treatment patterns across the study period
were modeled using a general linear model with the
monthly dose per week as the dependent variable and the
month as the independent variable. Monthly prescription
Table 2 ESA prescribing for hemodialysis patients by





ESA dose Before and after FDA
≥ 30,000
U/week
Black box warning *
Overall Base period Followup
% Mean Std_dev Mean Std_dev
All 20.8 19,486 23,742 18,191 21,581
Age (Year)
18–44 24.7 21,999 27,397 20,485 24,250
45–64 21.8 20,223 24,668 18,746 22,331
≥ 65 18.8 18,237 21,785 17,106 20,056
Race
White 19.5 18,427 22,794 17,229 21,008
Non-white 22.3 20,760 24,774 19,350 22,195
Gender
Male 20.3 18,956 23,937 17,733 21,620
Female 21.3 20,093 23,502 18,729 21,522
Diabetes
Co-morbidity
Diabetic 20.7 19,541 23,223 18,154 21,094
Non-diabetic 20.8 19,443 24,141 18,221 21,964
Facility profit status
For-profit 22.3 20,943 24,241 19,514 21,927
Non-profit 13.9 13,481 20,496 12,185 18,797
Facility chain status
Chain 1 (FP) 24.5 23,509 26,658 20,680 22,316
Chain 2 (FP) 22.6 21,071 23,277 20,086 22,043
Medium chains 22.2 20,229 23,350 19,198 22,028
Small/nonchains 17.7 16,850 21,561 15,713 20,029
Hospital-based (NP) 9.9 10,364 19,605 7,700 16,809
Hematocrit value#
< 30% 56.2 40,898 37,024 40,443 31,675
30 – < 36% 24.9 22,807 24,698 21,048 21,596
≥ 36% 13.6 16,383 18,621 13,041 14,971
Notes: FP For-profit, NP Nonprofit.
Base Period from September 2004 to February 2007. Followup from March
2007 to August 2009.
* P-value based on t-test comparison between base year and followup period
within covariate levels was <.0001 for all variables.
# See Footnote from Table 1.
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ESA dose by the number of days in each dialysis claim
(typically 30) and multiplying by 7 to calculate the weekly
dose per month. These monthly ESA dose per week were
then used to determine an average monthly ESA dose per
week for the entire population.An interrupted time series model using the AUTOREG
procedure in SAS was used to evaluate changes in average
ESA dosages in the 30 months prior (base) and 30 months
subsequent (followup) to the FDA black box warning as
follows [12]:
Y ¼ Beta0 þ Beta1 m1þ Beta2 m2þ Beta3  x1
Where Y is the average ESA dose per week in each
study month; Beta0 estimates ESA prescribing at the
beginning of the study period; Beta1 estimates change in
ESA prescribing in each month before the FDA warnings
(m1 study months in period 1); Beta2 estimates change in
ESA prescribing in each month after the FDA warnings
(m2 study months in period 2); Beta3 estimates the change
in ESA prescribing level following the FDA warnings
(x1 is an indicator variable (0 for period one and 1 for
period two)).
In our model, we took into account autocorrelations of
the prescribing patterns along the time period. We built
our model using a maximum likelihood method with
two autocorrelation lags. The first order autocorrelation
coefficient was significantly different from zero for almost
all models. Time series sometimes exhibit seasonality or
seasonal fluctuations. We tested for seasonality using proc
spectra in SAS against white noise of the residuals from
the models and found the residuals from our models were
consistent with white noise that indicated that no extra
seasonality modeling was needed [13]. In some cases,
models need to be corrected for lagged effects (i.e., the
effect of an intervention might take time to appear).
However, in our study, the FDA black box warning was
immediately reported to all nephrologists through the
Dear Doctor letters, therefore no lag effects were entered
into our main model, although possible random lag effects
were modeled through serial correlations.
Results and discussion
Descriptive statistics
Across the study period, the study population was pre-
dominately elderly (49%), white (55%), male (54%), had a
duration of dialysis greater than 3 years (50%), were
nondiabetic (56%), received dialysis services from for-profit
facilities (81%), from one of the two largest for-profit
chains (27% and 30%, respectively), and had hematocrit
values between 30-36%, within the FDA recommended
range (comprising 46% of the study population) or higher
(46%) (Table 1).
Although statistically significant, there were only minor
differences in patient demographics (age, race and gender),
duration of dialysis, and presence of diabetes between the
base and followup study periods. While the proportion of
patients who received dialysis services in for profit vs. not
for profit centers remained nearly the same in the base
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appeared to have grown substantially while medium
sized chains (defined as chains with 10 to 100 facilities)
decreased. There was also a shift in patient hematocrit
values between the base and followup study periods; the
proportion of patients with values greater than 36% was
reduced from 51% to 41%, while those in the 30- < 36%
category increased from 42% to 50%. The proportion of
anemic patients (<30%) remained ~7-9% during the study
period. The aggregate number of patients receiving an
ESA prescription (or a zero dose) per month was within
the range of 215,444 to 238,697 throughout the study
period (data not shown), suggesting no major exogenous
change in terms of population size (Table 1).
Unadjusted analyses and covariate effects
Overall, there was a significant 7% decrease in average
ESA dose between the base and followup 30-month
periods for all dialysis patients (19,486 versus 18,191
units/week; Table 2). Most covariate strata also
showed a decline in average dose between the two
periods (P < 0.0001), except for Chain 3. Notably, Chain 3
(the largest nonprofit chain), which administers ~4.4% of
all ESA doses, administered the lowest mean ESA dose
both in the base and follow up periods compared to other
medium and large dialysis facilities. Overall, nonprofit and
hospital-based facilities had the lowest average base and
followup ESA doses. Hospital-based facilities are anomal-
ous, however, due to their small size, sicker population,
and disproportionate use of darbepoetin, a different form
of ESAs that is longer acting was not included in this
study.
Younger, nonwhite and new patients were most likely to
be prescribed a higher ESA dose (≥ 30,000 units/week,
reflecting the highest ESA dose quartile) (P < 0.0001). Not
unexpectedly, patients with the lowest hematocrit levels
were significantly more likely to receive a higher ESA dose
(P < 0.0001). For profit facilities in general and the two
largest for profit chains prescribed higher ESA doses
(P < 0.0001) (Table 2).
Interrupted time series results
A model was performed to determine if the average 7%
observed decline in ESA dose was consistent with a
change in dosing practice as of the FDA black box warning.
Model results shown in Table 3 include a general trend in
ESA dose/week for each month in the base period prior to
the warnings (Beta1), a general trend in ESA dose/week
for each month in the followup period after the warnings,
often referred to as ‘sustainability’ (Beta2), and a post
intervention change (or shift) in ESA dose/week level
immediately after the warnings (Beta3).
The FDA black box warning did not appear to influence
ESA prescribing among the overall US dialysis population.Model results show the declining trend in month-to-month
ESA dose was not statistically significant both before and
after the FDA warnings. The drop in ESA dose level after
the warnings was also not significant (Figure 1 and first
row Table 3). Stratification by patient demographics,
clinical and facility characteristics suggest a differential
impact in the effect of the FDA black box warning on
ESA prescribing. Only a few covariates had statistically
significant findings linked to the FDA warnings. For
example, patients with a hematocrit ≥36% had a declining
month-to-month trend both before (−164 units/week,
p = <.0001) and after the warnings (−80 U/wk, p = .001),
and a large drop in ESA levels after the warnings (−4,744
U/wk, p = <.0001) (Figures 2 and Table 3). In contrast,
patients with a hematocrit <30% had a large increase in
ESA dose level after the warnings (6,220 U/wk, p = .013),
consistent with an increasing month-to-month trend
before the warnings (224 units/week, p = .01). After the
warnings, there was no significant decline in trend in
ESA prescribing for patients with a hematocrit <30%.
For patients within the FDA-recommended hematocrit
range of 30 – 36%, the change in ESA level immediately
after the warnings was not significant, but there was a
decline in month-to-month trend after the warnings
(−103 U/wk, p =0.014).
The other area of significant findings and wide
variation in response to FDA warnings is dialysis facility
organizational status (Figure 3 and Table 3). ESA pre-
scribing trend in not-for profit facilities declined month-
to-month before the warnings (−90 units/week, p = .009),
with a significant drop in ESA dose immediately after the
warnings (−2,487 U/wk, p = <.015). In contrast, there was
no evidence of change in ESA prescribing linked to the
black box warning among for-profit facilities overall
(Table 3). Each of the three largest US dialysis chains
responded differently to the FDA warnings. Chain 1
patients experienced a declining month-to-month trend
before (−90 units/week, p = .004) and after the warnings
(−103 U/wk, p = .002), and a drop in ESA dose level after
the warnings (−2,148 U/wk, p = .017). Chain 2 patients
experienced no change in ESA prescribing before or
after the warnings. And Chain 3 patients experienced an
increasing month-to-month trend before the warnings
(94 U/wk, p = .041), and an increase in the ESA dose
level after the warnings (3,189 U/wk, p = .016), followed
by a flat insignificant trend.
Since ESA dose is sometimes withheld for a particular
month as a means of lowering the hematocrit back to
the target range, the extent to which dose withholding
changed before and after the FDA black box warning is
noteworthy. We found only a small increase in the
frequency of patient months with zero ESA doses
(withholding) in the 30 months after the FDA Black Box
warning compared to the 30 months before (12.5% versus
Table 3 Results of interrupted time series model for selected variables
Change in ESA/week each month
prior to black box warning
Change in ESA/week each
month post black box warning
Change in ESA/eeek Level
after black box warning
Beta1 SD p-value Beta2 SD p-value Beta3 SD p-value
All -37 25.8 0.162 -41 27.6 0.146 -882 773.9 0.260
Hematocrit value
< 30% 224 84.1 0.010 -137 85.7 0.114 6220 2423.0 0.013
30 - < 36% 46 38.1 0.232 -137 85.7 0.114 6220 2423.0 0.013
≥ 36% -164 23.0 <.0001 -80 23.0 0.001 -4744 648.2 <.0001
Facility profit status
For-profit -31 27.7 0.271 -49 30.2 0.109 0.109 835.2 0.440
Non-profit -90 33.2 0.009 -30 32.7 0.363 -2487 985.4 0.015
Facility chain status ^
Large chains
Chain 1 (FP) -90 30.0 0.004 -103 31.8 0.002 -2148 870.9 0.017
Chain 2 (FP) -15 35.4 0.673 -27 37.7 0.480 -61 1060.0 0.954
Chain 3 (NP) 94 44.9 0.041 43 44.6 0.343 3189 1288.0 0.016
Medium chains 72 26.2 0.008 -97 26.5 0.001 1703 752.6 0.028
Small/nonchain -6 24.8 0.797 -49 24.9 0.055 -432 723.3 0.553
Notes: SD Standard Deviation, FP For-profit, NP Nonprofit.
Variables included in Table 3 were selected based on one or more significant Beta value (p < 0.05).
Model intercept coefficient for all variables in Table 1 is significant (p < 0.0001). Since the time after the FDA warnings is not orthogonal to Beta3, the slope after
the warnings (Beta2) is conditioned on the change in level (Beta3).
^ Large chains (Chain 1 - Chain 3) are defined as 100 or more units. Medium chains defined as 10 to ≤ 99 units. Small/Nonchains defined as < 10 units.
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FDA Black Box Warning on ESA Therapy
March, 2007
Figure 1 ESA units/week per month for the US hemodialysis population from September 2004 to August 2009.
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FDA Black Box Warning
on ESA Therapy
March, 2007
Figure 2 ESA units/week per month for the US hemodialysis population from September 2004 to August 2009 by hematocrit level.
Given the different dosing levels based on hematocrit level, we used a different scale for the Y axis for each hematocrit category, although each
covered a range of ~10,000 ESA units.
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tivity analyses including non-zero dose only in the analysis
and the results were similar to those reported above. We
also used ESA dose per administration (versus dose per
week) as the study measure and found similar results. We
conducted other models such as a segmented regression
approach and the results were very similar to the ITS
model reported in the paper.
Conclusion
Although there was a decline in ESA dose across the
60-month study period, the FDA black box warning issued
in March 2007 did not appear to influence ESA prescribing
for the overall dialysis population. However, for patients
with the highest hematocrit values and for those receiving
treatment in certain dialysis facilities, nephrologists and
dialysis providers were more likely to heed the FDA black
box warning.The FDA black box warning issued for ESA therapy
included the following important study results: “Patients
with chronic kidney failure had an increased number of
deaths and of non-fatal heart attacks, strokes, heart failure,
and blood clots when ESAs were adjusted to maintain
higher red blood cell levels (hemoglobin more than
12 g/dL).” A new patient medication guide accompanied
the warnings and posed the following question and answer,
‘What is the most important information I should know
about Epogen? Using Epogen can lead to death or other
serious side effects’ [14]. Given these warnings, our find-
ings raise questions as to why providers did not lower ESA
doses further than we observed when faced with mounting
evidence of risks [7,8,15-18]. Prior to the warnings, and
during our study, although the FDA recommended a target
hematocrit of 30 – 36%, studies suggested that providers
often overshot the high end of this target range given
Medicare’s reimbursement policy allowed hematocrit to be
Chain 1 (FP)
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FDA Black Box Warning
on ESA Therapy
March, 2007
Figure 3 ESA units/week per month for the US hemodialysis population from September 2004 to August 2009 by facility
organizational status. The straight solid line is for the trend derived from the interrupted time series regression model, the cross (+) is the
observed value and the diamond (♦) is the predicted value based on the interrupted time series model. The model parameters for all figures are
presented in Table 3.
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source of profit, particularly for large dialysis chains that
were also able to recoup large rebates and receive dis-
counts [21], producing the second largest source of facility
income of ~22% [22]. For instance, a spike in ESA dose
evident in the beginning of 2006, also confirmed by
USRDS data [23], appears to be associated with a new
lower payment method for ESA therapy that changed from
a per-unit rate to a 6 percent above manufacturers’ average
sales price (ASP) [24]. During our study period, ESA the-
rapy continued to be reimbursed on a fee-for service basis,
creating a financial incentive for increased utilization of
this therapy.
Although USRDS data show a decline in both ESA
dose and hematocrit levels following the issuance of the
FDA black box warning, it remained unclear, until now,whether these results were related to the FDA warnings
or rather which groups, if any, benefited from the FDA
warnings. Patients who had the highest hematocrit
values showed the largest shift or decline in ESA dose
level after the FDA warning with a drop of 4,744 U/week,
perhaps because providers were concerned about their
safety given publication of CHOIR [7] and CREATE [8]
findings in mid-November 2006, showing potential harm
and no benefit for ESA therapy, respectively. It is note-
worthy, however, that on average the percentage of pa-
tients with a monthly hematocrit reading above 36%
declined from 51% to 41%, following the FDA warnings.
Given the appropriate goals of ESA therapy, two in five
patients had hematocrit levels deemed unacceptably high
in the 30 months following the FDA black box warning.
For ESA-resistant patients, those with the highest doses
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ESA dose level immediately after the warnings (and no
subsequent significant decline in ESA trend); findings con-
trary to the FDA black box warning. Perhaps providers felt
justified not to decrease dose for their resistant patients
after the warnings given the black box emphasis on
avoiding transfusions which are sometimes triggered at a
hematocrit threshold of ~27-30% for patients with serious
co-morbidities [25]. High hematocrit levels appear to be
of more concern to nephrologists than high ESA doses
following the black box warnings. Implications of these
findings require further investigation.
Variations in treatment practice patterns across more
than 4,000 US dialysis facilities are well established and
controversial [15,26-31]. In our study, nonprofit faci-
lities overall had a declining trend before the warnings
and a large drop in ESA dose immediately afterwards. In
contrast, for-profit facilities overall that prescribed
higher ESA doses in both the period before and after the
FDA warnings compared to nonprofit facilities -- on
average 19,514 versus 12,185 U/week in the post war-
ning period – did not change their ESA prescribing re-
lated to the FDA warnings. However, not all for-profit
facilities responded similarly to the FDA warnings. Du-
ring our study, two-thirds of dialysis patients received
treatment in one of two large for-profit dialysis chains.
Notably, one chain had significant declines in ESA doses
consistent with FDA black box warnings and the other
chain did not. Chains are owned by different entities
that make individual corporate decisions regarding
anemia protocols and anemia management goals among
their patients.
Evidence of adverse events commonly emerges after a
drug has been on the market for several years necessita-
ting the issuance of a black box warning [32]. According
to Green et al. [33], there are three categories of factors
relevant to behavior change among physicians: predis-
posing factors (communicating or disseminating infor-
mation); enabling factors (facilitating the desired change
in the practice site); and reinforcing factors (by reminders
or feedback). The model suggests that interventions that
are most successful in changing physician practice are
those that use enabling strategies or reinforcing methods
in addition to predisposing or disseminating strategies.
For example, a FDA black box warning on ESA use for
oncology patients was also released on March 2007, and
included a mandate that providers engage in a risk/benefit
discussion with the patient and document that this discus-
sion occurred by completing and signing the Patient
Acknowledgment Form; a more stringent requirement
that is absent from dialysis provider ESA prescribing. In
contrast to the results presented herein, ESA use for
oncology patients plummeted following the black box
warning [34,35].After nearly three decades of the same ESRD payment
system, an enhanced ESRD Prospective Payment System
(PPS) was initiated in January 2011 bundling separately
billable items (primarily ESA therapy) into the larger
dialysis composite rate [36]. Under PPS, facilities have
no financial incentive to use more drugs than are clini-
cally necessary. We anticipate that changes in reim-
bursement rates will have a greater impact on access and
reduced exposure to ESA therapy compared to the
March 2007 FDA black box warning. Indeed, early indi-
cations suggest that both ESA use [37] and hematocrit
levels have been dramatically reduced since implementa-
tion of ESRD PPS [38].
Several study limitations are noteworthy, however.
One, when ESRD patients are hospitalized, on average
twice a year, information on ESA dosing is not available.
Two, the analysis was confined to those individuals with
Medicare as the primary payor, therefore the gene-
ralizability to other payers is limited. And three, because
of the exploratory nature of our analysis, we did not
adjust for the size of type I error rate in conducting mul-
tiple statistical tests. One way to address the potential
threat regarding the validity of an interrupted time series
by historical/secular shifts is to compare, in our case,
ESA drug doses to drug dosing of other profitable injec-
table drugs that should not be affected by the FDA war-
ning (e.g., injectable vitamin D or iron). After increasing
each year since 1992 (including growth of 11–19% in
2002–2004) to reach nearly $2 billion, Medicare ESA
costs (a surrogate for use) were stable in 2004–2007,
and in 2008 declined to a pre-2004 level of $1.8 billion.
Conversely, use of other intravenous drugs continued to
increase in 2008 — 12% for IV vitamin D, 4.8% for IV
iron, and 13.2% for other injectables [39].
ESA therapy had been both profitable for providers
and controversial regarding benefits for nearly two de-
cades. The extent to which a FDA black box warning
highlighting important safety concerns influenced use of
ESA therapy among nephrologists and dialysis providers
was unknown. Our study found no evidence of changes
in ESA prescribing for the overall dialysis population
resulting from a FDA black box warning.
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